Abstract:Despite receiving antiretroviral therapy, most patients with HIV still have latent reservoirs of the virus; here, these reservoirs are shown to be dominated by viruses with cytotoxic T lymphocyte escape mutations, with potential implications for the development of therapeutic vaccines. Antiretroviral therapy does not cure HIV-1 infection: despite drug treatment, most patients still have latent reservoirs of the virus. This study of immune cells isolated from 30 HIV-1-infected patients who had been on antiretroviral therapy for at least two years and had maintained undetectable plasma HIV-1 RNA levels, shows that these viral reservoirs are dominated by viruses with cytotoxic T lymphocyte escape mutations. This finding implies that future directions in therapeutic vaccine design may need to focus on boosting broad cytotoxic T lymphocyte responses. Despite antiretroviral therapy (ART), human immunodeficiency virus (HIV)-1 persists in a stable latent reservoir1,2, primarily in resting memory CD4+ T cells3,4. This reservoir presents a major barrier to the cure of HIV-1 infection. To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed5 and tested both in vitro and in vivo6,7,8. A key remaining question is whether virus-specific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells in ART-treated patients after latency is reversed. Here we show that there is a striking all or none pattern for CTL escape mutations in HIV-1 Gag epitopes. Unless ART is started early, the vast majority (>98%) of latent viruses carry CTL escape mutations that render infected cells insensitive to CTLs directed at common epitopes. To solve this problem, we identified CTLs that could recognize epitopes from latent HIV-1 that were unmutated in every chronically infected patient tested. Upon stimulation, these CTLs eliminated target cells infected with autologous virus derived from the latent reservoir, both in vitro and in patient-derived humanized mice. The predominance of CTL-resistant viruses in the latent reservoir poses a major challenge to viral eradication. Our results demonstrate that chronically infected patients retain a broad-spectrum viral-specific CTL response and that appropriate boosting of this response may be required for the elimination of the latent reservoir.

The reservoir of latent HIV

Research progress on HIV latency-reversing agents and its mechanism

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies

Identification of CD98 As a Novel Biomarker for HIV-1 Permissiveness and Latent Infection

Research Progress on Human Immunodeficiency Virus Type 1 Latent Infection Activator

Research progress on human immunodeficiency virus reservoir and its eradication

Broad CTL Response is Required to Clear Latent HIV-1 Due to Dominance of Escape Mutations

Research progress on measuring the latent reservoir of human immunodeficiency virus

The multifaceted nature of HIV tissue reservoirs

The neglected brain reservoirs：a barrier to an HIV cure

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

Eliminating the HIV tissue reservoir: current strategies and challenges

[Research advances in evaluation and measurement techniques of latent human immunodeficiency virus reservoirs]

HIV Tissue Reservoirs: Current Advances in Research

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

The Hidden Enemy Within: Uncovering the Secrets of HIV Tissues Reservoirs and Current mRNA Vaccine Development

The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy

Targeting HIV persistence in the tissue

Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.